Generic Name and Formulations:
Cefotetan disodium 1g, 2g; IM or IV inj; sodium content 3.5mEq/g.
Indications for CEFOTAN:
Susceptible lower respiratory tract or urinary tract, skin and skin structure, bone and joint, gynecologic, intraabdominal infections. Surgical prophylaxis.
IV: inject over 3–5mins. UTI: 500mg IV or IM every 12hrs or 1–2g IV or IM every 12–24hrs. Mild to moderate skin and skin structures: 2g IV every 24hrs or 1g IV or IM every 12hrs. Severe skin and skin structure: 2g IV every 12hrs. Other sites: 1–2g IV or IM every 12hrs. Severe: 2g IV every 12hrs. Life threatening: 3g IV every 12hrs; max 6g/day. Prophylaxis: 1–2g IV once 30–60 mins before surgery. CrCl <30mL/min: reduce dose or frequency, see full labeling. Hemodialysis: give ¼ of the usual dose every 24hrs on days between dialysis and ½ the usual dose on dialysis days.
Previous cephalosporin-associated hemolytic anemia.
Penicillin or other allergy. Discontinue if allergic reaction occurs. Have epinephrine and other emergency measures available. Renal impairment. Renal or hepatobiliary dysfunction, poor nutritional state, cancer patients, or elderly: monitor prothrombin time. Monitor for hemolytic anemia or superinfection with prolonged use. GI disease (esp. colitis). Pregnancy (Cat.B). Nursing mothers.
Avoid alcohol for 72 hours after dosing. Increased nephrotoxicity with concomitant aminoglycoside; monitor renal function. May cause false (+) Clinitest, Benedict's or Fehling's soln. May interfere with creatinine tests.
Diarrhea, nausea, rash, itching, local reactions, anaphylaxis, blood dyscrasias, elevated liver enzymes, fever; C. difficile-associated diarrhea.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC